Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release : Roche presents new data at World -2-

09/24/2021 | 01:00am EDT

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Group Media Relations

Phone: +41 61 688 8888 / e-mail: https://www.globenewswire.com/Tracker?data=LPdjRf6ydjxzA4tS7yOfBaY7_jWXBYJZ2eXqa9a1xDnhHG4dakNYDzb_Q7snOgID9RKdS_vbshZ4PmqYzKqQFAxXZrMekR9WyTUivIQ2nSAf1nMzolTjySYmVKNqJw8K media.relations@roche.com

 
Dr. Nicolas Dunant          Patrick Barth 
 Phone: +41 61 687 05 17     Phone: +41 61 688 44 86 
Dr. Barbara von Schnurbein  Karsten Kleine 
 Phone: +41 61 687 89 67     Phone: +41 61 682 28 31 
Nina Mählitz           Nathalie Meetz 
 Phone: +41 79 327 54 74     Phone: +41 61 687 43 05 
 
 
Roche Investor Relations 
Dr. Karl Mahler                               Jon Kaspar Bayard 
 Phone: +41 61 68-78503                        Phone: +41 61 68-83894 
 e-mail: mailto:karl.mahler@roche.com          e-mail: mailto:jon_kaspar.bayard@roche.com 
 karl.mahler@roche.com                         jon_kaspar.bayard@roche.com 
--------------------------------------------  ------------------------------------------- 
Dr. Sabine Borngräber                    Dr. Bruno Eschli 
 Phone: +41 61 68-88027                        Phone: +41 61 68-75284 
 e-mail: mailto:sabine.borngraeber@roche.com   e-mail: mailto:bruno.eschli@roche.com 
 sabine.borngraeber@roche.com                  bruno.eschli@roche.com 
--------------------------------------------  ------------------------------------------- 
Dr. Birgit Masjost                            Dr. Gerard Tobin 
 Phone: +41 61 68-84814                        Phone: +41 61 68-72942 
 e-mail: mailto:birgit.masjost@roche.com       e-mail: mailto:gerard.tobin@roche.com 
 birgit.masjost@roche.com                      gerard.tobin@roche.com 
--------------------------------------------  ------------------------------------------- 
 
Investor Relations North America 
Loren Kalm 
 Phone: +1 650 225 3217 
 e-mail: mailto:kalm.loren@gene.com 
 kalm.loren@gene.com 
-------------------------------------------- 
 

Attachment

   -- 24092021_MRE_Evrisdy WMS_EN 
      https://ml-eu.globenewswire.com/Resource/Download/71d19b05-28ae-4fa7-807b-44992bad6003 
 
 
 

(END) Dow Jones Newswires

September 24, 2021 01:00 ET (05:00 GMT)

All news about ROCHE HOLDING AG
01:53aROCHE : Wins US FDA Nod For VENTANA Test In Non-Small Cell Lung Cancer Patients
MT
01:00aROCHE : VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to ide..
AQ
01:00aPRESS RELEASE : Roche's VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion d..
DJ
10/21CHUGAI PHARMACEUTICAL : Contribution of Para-transit Vehicles to Welfare Services
AQ
10/21ROCHE : Chugai Pharmaceutical Co., Ltd. - F. Hoffmann-La Roche Announces Third Quarter Sal..
AQ
10/21ROCHE HOLDINGS AG : JP Morgan sticks Neutral
MD
10/21ROCHE HOLDINGS AG : Credit Suisse reiterates its Neutral rating
MD
10/20ROCHE HOLDINGS AG : Bernstein reiterates its Buy rating
MD
10/20ROCHE HOLDINGS AG : Goldman Sachs reiterates its Buy rating
MD
10/20ROCHE HOLDINGS AG : Barclays gives a Buy rating
MD
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2021 62 027 M 67 636 M 67 636 M
Net income 2021 14 749 M 16 083 M 16 083 M
Net cash 2021 4 505 M 4 913 M 4 913 M
P/E ratio 2021 20,3x
Yield 2021 2,62%
Capitalization 312 B 339 B 340 B
EV / Sales 2021 4,95x
EV / Sales 2022 4,80x
Nbr of Employees 101 465
Free-Float 83,5%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 357,80 CHF
Average target price 383,40 CHF
Spread / Average Target 7,16%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG15.79%339 425
JOHNSON & JOHNSON3.83%430 148
PFIZER, INC.16.27%240 303
NOVO NORDISK A/S56.55%239 079
ELI LILLY AND COMPANY42.84%218 640
MERCK & CO., INC.-0.77%205 472